CryoPort (NASDAQ:CYRX) Insider Sells $25,880.00 in Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Mark Sawicki sold 3,235 shares of CryoPort stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the sale, the insider directly owned 103,697 shares in the company, valued at $829,576. This represents a 3.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

CryoPort Price Performance

CYRX stock opened at $8.29 on Friday. The business has a 50-day moving average of $9.10 and a 200-day moving average of $9.35. CryoPort, Inc. has a fifty-two week low of $4.63 and a fifty-two week high of $11.45. The stock has a market capitalization of $413.34 million, a P/E ratio of 6.28 and a beta of 1.69.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $45.45 million for the quarter, compared to analyst estimates of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. Equities analysts expect that CryoPort, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

Several brokerages have commented on CYRX. Wall Street Zen cut shares of CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research report on Monday, December 29th. Finally, Needham & Company LLC increased their price target on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.94.

Institutional Trading of CryoPort

A number of large investors have recently added to or reduced their stakes in CYRX. Basepoint Wealth LLC bought a new position in shares of CryoPort in the 4th quarter valued at about $34,000. Whittier Trust Co. of Nevada Inc. bought a new stake in shares of CryoPort in the 3rd quarter valued at about $53,000. Tower Research Capital LLC TRC lifted its stake in CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock valued at $44,000 after purchasing an additional 4,375 shares during the last quarter. AlphaQuest LLC bought a new position in CryoPort during the third quarter worth about $79,000. Finally, ProShare Advisors LLC acquired a new position in CryoPort during the second quarter worth approximately $75,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.